Introduction: Many Chinese patients who are uncontrolled by oral antidiabetic drugs (OADs) receive short-term intensive insulin therapy (IIT) in hospital to rapidly relieve glucose-associated toxicity and to preserve/improve β-cell function. However, evidence for optimizing insulin algorithms for maintenance treatment after IIT is lacking. This study will compare the efficacy and safety of basal insulin-based treatment versus twice-daily premixed insulin in type 2 diabetes mellitus (T2DM) patients after short-term in-hospital IIT.
Methods: This 26-week randomized, multicenter, positive-controlled, open-label, parallel-group study will enroll approximately 400 male and female patients aged 18-70 years with poorly-controlled T2DM (HbA1c > 7.5%) despite treatment with metformin plus at least one other OAD for 8 or more weeks. During a run-in period of 7-10 days, patients will be treated in-hospital with IIT comprising insulin glargine (Lantus) once daily and insulin glulisine (Apidra) three times daily; both regimens will be titrated daily to achieve the glycemic goal. Eligible patients will then be randomized in a 1:1 ratio to insulin glargine plus OADs or twice-daily premixed insulin (NovoLog Mix 70/30) for 24 weeks, with metformin maintained throughout the study in both treatment groups. The primary endpoint is HbA1c change from baseline to week 24. Secondary endpoints include assessment of fasting plasma glucose, total daily insulin dose, hypoglycemia incidence, body weight change, adverse events, and patient satisfaction.
Discussion: Given the current lack of clinical data, this study will provide evidence supporting safe and effective glycemic control using basal insulin glargine-based therapy plus OADs compared with twice-daily premixed insulin in Chinese patients with T2DM after short-term IIT. This will assist physicians by providing a wider choice of treatments.
Trial Registration: ClinicalTrials.gov identifier, NCT03359837 (registered on 2 December 2017).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12325-020-01265-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diet supplementation with a mixture of essential oils: Effects on enteric methane emissions, apparent total-tract nutrient digestibility, nitrogen utilization, and lactational performance.
J Dairy Sci
January 2025
Agriculture and Agri-Food Canada, Quebec Research and Development Centre, Quebec, QC G1V 2J3 Canada.
This study examined the effects of supplementing dairy cows with a mixture of essential oils on enteric CH emissions, apparent total-tract nutrient digestibility, N utilization, and lactational performance (production, components and efficiency). Thirty-two multiparous lactating Holstein cows were used in a randomized complete block design. Cows averaged (mean ± SD) 95 ± 15.
View Article and Find Full Text PDFGlycaemic outcomes in hospital with IDegAsp versus BIAsp30 premixed insulins.
Intern Med J
August 2024
Department of Diabetes and Endocrinology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Background And Aims: IDegAsp (Ryzodeg 70/30), a unique premixed formulation of long-acting insulin degludec and rapid-acting insulin aspart, is increasing in use. Management of IDegAsp during hospitalisation is challenging because of degludec's ultra-long duration of action. We investigated inpatient glycaemia in patients treated with IDegAsp compared to biphasic insulin aspart (BIAsp30; Novomix30).
View Article and Find Full Text PDFPractical guide in using insulin degludec/insulin aspart: A multidisciplinary approach in Malaysia.
Malays Fam Physician
May 2023
MBBS (Adelaide), MRCP (UK), MMedSci (University of Sheffield), FRCP (Edinburgh), Universiti Sains Malaysia Hospital, Jalan Raja Perempuan Zainab II, Kubang Kerian, Kota Bharu, Kelantan, Malaysia.
Insulin degludec/insulin aspart (IDegAsp) co-formulation provides both basal and mealtime glycaemic control in a single injection. The glucose level-lowering efficacy of IDegAsp is reported to be superior or non-inferior to that of the currently available insulin therapies with a lower rate of overall hypoglycaemia and nocturnal hypoglycaemia. An expert panel from Malaysia aims to provide insights into the utilisation of IDegAsp across a broad range of patients with type 2 diabetes mellitus (i.
View Article and Find Full Text PDFAdvancing therapy in people with suboptimally controlled basal insulin-treated type 2 diabetes: Subanalysis of the SoliMix trial in participants in Latin American countries.
Diabetes Obes Metab
September 2023
Medical Department, Sanofi, Mexico City, Mexico.
Aims: This subanalysis of the SoliMix trial assessed the efficacy and safety of advancing basal insulin (BI) therapy with iGlarLixi versus BIAsp 30 in people with type 2 diabetes (T2D) living in Latin American (LATAM) countries, i.e. Argentina and Mexico (N = 160).
View Article and Find Full Text PDFRegimen comprising GLP-1 receptor agonist and basal insulin can decrease the effect of food on glycemic variability compared to a pre-mixed insulin regimen.
Eur J Med Res
December 2022
Institute of Statistics, National Chiao Tung University, Hsinchu, Taiwan.
Background: Increasing evidence suggests that glucagon-like peptide 1 (GLP-1) receptor agonists (RA) can stabilize glycemic variability (GV) and interfere with eating behavior. This study compared the impact of insulin, GLP-1 RA, and dietary components on GV using professional continuous glucose monitoring (CGM).
Methods: Patients with type 2 diabetes underwent CGM before and after switching from a twice-daily pre-mixed insulin treatment regimen to a GLP-1 RA (liraglutide) plus basal insulin regimen.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!